Page last updated: 2024-11-08

ajugarin i

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ajugarin I: a clerodane diterpene; the major component of the shrub Ajuga remota; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
AjugagenusA plant genus of the family LAMIACEAE that contains cyasterone, ajugasterone, 20-hydroxyecdysone, 8-acetylharpagide (an iridoid glycoside).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID173866
CHEMBL ID494606
CHEBI ID2527
MeSH IDM0243722

Synonyms (19)

Synonym
ajugarin-i
C09058 ,
ajugarin i
62640-05-5
CHEMBL494606 ,
ajugarin-1
chebi:2527 ,
[(4r,4ar,5s,7r,8s,8ar)-5-acetyloxy-7,8-dimethyl-8-[2-(5-oxo-2h-furan-3-yl)ethyl]spiro[2,3,5,6,7,8a-hexahydro-1h-naphthalene-4,2'-oxirane]-4a-yl]methyl acetate
AC1L5AM1 ,
2(5h)-furanone, 4-(2-(8-(acetyloxy)-8a-((acetyloxy)methyl)octahydro-5,6-dimethylspiro(naphthalene-1(2h),2'-oxiran)-5-yl)ethyl)-, (1r-(1alpha,4abeta,5beta,6alpha,8alpha,8aalpha))-
unii-29uw6ah176
29uw6ah176 ,
2(5h)-furanone, 4-(2-((1r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-((acetyloxy)methyl)octahydro-5,6-dimethylspiro(naphthalene-1(2h),2'-oxiran)-5-yl)ethyl)-
ajugarin-i [mi]
(1r-(1.alpha.,4a.beta.,5.beta.,6.alpha.,8.alpha.,8a.alpha.))-4-(2-(8-(acetyloxy)-8a-((acetyloxy)methyl)octahydro-5,6-dimethylspiro(naphthalene-1(2h),2'-oxiran)-5-yl)ethyl)-2(5h)furanone
ajugarin
Q27105704
DTXSID40978198
AKOS040750254
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
butenolideA gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID358968Selectivity index, ratio of ED50 for human A431 cells to IC50 for chloroquine-sensitive Plasmodium falciparum FCA10/GHA2002Journal of natural products, May, Volume: 65, Issue:5
The antiplasmodial activity of isolates from Ajuga remota.
AID358967Cytotoxicity against human A431 cells by MTT assay2002Journal of natural products, May, Volume: 65, Issue:5
The antiplasmodial activity of isolates from Ajuga remota.
AID358965Antiplasmodial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum FCA10/GHA as LDH activity2002Journal of natural products, May, Volume: 65, Issue:5
The antiplasmodial activity of isolates from Ajuga remota.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]